A Randomised, Double-blinded, Placebo-controlled Study to Assess the Safety and Bioactivity of Sodium Polysulthionate (SG1002) in Heart Failure Patients

Trial Profile

A Randomised, Double-blinded, Placebo-controlled Study to Assess the Safety and Bioactivity of Sodium Polysulthionate (SG1002) in Heart Failure Patients

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2015

At a glance

  • Drugs Sodium polysulthionate (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Sulfagenix
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Nov 2015 Planned End Date changed from 1 Apr 2017 to 1 Jul 2018 as reported by ClinicalTrials.gov record.
    • 25 Nov 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top